ClearPoint Neuro (CLPT) Debt to Equity (2011 - 2026)

ClearPoint Neuro has disclosed Debt to Equity across 15 years of filings, most recently posting $2.63 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $2.63, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.63 (changed N/A YoY), and the FY2025 annual result was $1.75, changed N/A from the prior year.
• Debt to Equity came in at $2.63 for Q1 2026 at ClearPoint Neuro, up from $1.75 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $2.63 in Q1 2026 to a low of $0.22 in Q1 2022.
• The 4-year median for Debt to Equity is $0.39 (2023), against an average of $0.85.
• Across the five-year window, Debt to Equity sank 61.35% in 2022 and surged 75.2% in 2023, its largest moves.
• ClearPoint Neuro's Debt to Equity stood at $0.27 in 2022, then soared by 75.2% to $0.47 in 2023, then soared by 272.75% to $1.75 in 2025, then soared by 50.44% to $2.63 in 2026.
• The last three Debt to Equity figures came in at $2.63 (Q1 2026), $1.75 (Q4 2025), and $1.84 (Q3 2025), per Business Quant data.